Efficacy of Two-Week Therapy With Bismuth Quadruple Versus Levofloxacin Concomitant for *Helicobacter Pylori* Infection: A Prospective Single-Center Randomized Controlled Trial.

Marouf Alhalabi (✉ e.marouf@hotmail.com)

Damascus Hospital

Mohammed Waleed Alassi

Damascus Hospital

Kamal Alaa Eddin

Damascus Hospital

Khaled Cheha

Damascus Hospital

Research Article

Keywords: *Helicobacter Pylori*, doxycycline, tinidazole, bismuth, quadruple regimen, levofloxacin, Syria

Posted Date: March 17th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-294572/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Antibiotic-resistance reduces the efficacy of conventional therapy for H.pylori infection worldwide, which necessitates using various protocols according to location. This was an open-label randomized controlled trial. We used two modified protocols, bismuth quadruple and concomitant levofloxacin. The aim was to compare the eradication rates of previous protocols as empirical first-line treatment to cure H.pylori infection in intention-to-treat (ITT) and per-protocol analyses (PPA) in Syrian population. We assigned seventy-eight eligible naïve patients, with a 1:1 ratio to receive two-week therapy of (bismuth subsalicylate 524 mg four times daily, doxycycline 100 mg, tinidazole 500 mg, and esomeprazole 20 mg, each twice daily) (B-group), or (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg, each twice daily) (L-group). We confirmed H.Pylori eradication by stool antigen test at eight weeks. According to IIT, the eradication rates were 76.92%, and 82.05%, for the B-group and L-group respectively. According to PPA, the eradication rates were 78.9%, and 82.1% for the B-group and L-group respectively. P-value was 0.78. We didn't report serious adverse effects. The eradication rates in both regimens were fair. Further trials are required to identify the preferred first-line treatment for H.pylori infection in the Syrian population.

Background:

Eastern Mediterranean region countries have a high prevalence rate of H.Pylori infection ¹. Chronic infection of H. Pylori contributes to multiple diseases such as peptic ulcer disease and subsequent bleeding ²⁻⁴, dyspepsia, gastric adenocarcinoma, ⁵ mucosa-associated lymphoid tissue (MALT) lymphoma ⁶, idiopathic thrombocytopenic purpura, and ⁷ unexplained iron deficiency anaemia. ⁸ World health organization has listed the H.Pylori infection as a class 1 carcinogen.⁹ Eradication of H.Pylori cures previous diseases and can decrease the risk of gastric cancer.¹⁰

The global rate of H. Pylori infection eradication is decreasing due to increased antibiotic resistance, particularly clarithromycin and levofloxacin. ¹¹. In the eastern Mediterranean area, the resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, and tetracycline were 29%,61%,23%,14%,10% respectively.¹² Several researchers reviewed many therapy regimens including sequential, concomitant, and hybrid to find the best treatment protocol. ¹³ The results of conventional triple therapy in Syria were disappointing. ¹⁴ Tetracycline is unavailable in Syria, therefore we used doxycycline in the bismuth quadruple regimen.^{15,16} Although tinidazole isn't superior to metronidazole in treating Helicobacter Pylori infections, we used tinidazole instead of metronidazole in both regimens, because H. pylori have a high metronidazole resistance rate. ¹⁷ and metronidazole is a commonly used drug in Syria for treating gynaecological and gastrointestinal diseases. We didn't perform a susceptibility test of H. Pylori to antibiotics, since it is not accessible in Syria or neighbouring countries. There is a lack of data about the efficacy of the modified bismuth quadruple regimen and modified levofloxacin-containing quadruple concomitant regimens in Syrian patients, so we conducted this trial to evaluate the efficacy and report the eradication rate according to intention to treat analysis (ITT) and per-protocol analysis (PPA).

Materials And Methods

This was a prospective single-center an open-label parallel blind randomized controlled trial.. This study was performed in the department of gastroenterology at Damascus hospital, Syria. We recruited appropriate candidates from patients who visited our clinic for evaluation of dyspeptic symptoms by upper gastrointestinal endoscopy between February 2020 and August 2020. Exclusion criteria were (1) younger than 18 years and older than 80 years; (2) prior eradication treatment for H pylori; (3) documented reactions to any of the studied medications ;(4) recent use of antibiotics, bismuth, or proton pump inhibitors (PPIs) in the preceding month; (5) pregnant or lactating women; (6) previous gastric surgery; (7) alcohol or opioid abuse; or (8) severe concurrent medical illnesses, such as liver failure, renal failure, or terminal malignancy. The Ethical Committee of Damascus hospital had approved the design and procedures of this research. We provide each patient with written informed consent before beginning the study procedure. We register this study as a standard randomized clinical trial (Clinicaltrial.gov, identifierNCT04348786, date:29-January-2020, <https://clinicaltrials.gov/ct2/show/NCT04348786>).

Intervention

Eligible patients were randomized in a 1:1 ratio to receive two-week therapy of either modified bismuth quadruple (B-group) or modified concomitant levofloxacin (L-group). The B-group obtained bismuth subsalicylate 524 mg q.i.d, doxycycline 100 mg, tinidazole 500 mg, esomeprazole 20 mg each b.i.d for 14 days. While the L-group obtained levofloxacin 500 mg q.d, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each b.i.d for 14 days. The indication of treatment relied on the American College of gastroenterology guideline and Maastricht V/Florence consensus report ^{13,15} including peptic ulcer, chronic gastritis, primary gastric MALT lymphoma, intestinal metaplasia, dyspepsia, and unexplained iron deficiency anaemia.

We used a Microsoft Excel function called (RANDBETWEEN) to generate a sequence of two randomized numbers, number one referred to the B-group, and number two referred to the L-group. We printed each code on separate paper and inserted it into sealed opaque envelopes in unchanged order, and held it in a secure locker belonging to an independent medical staff member. After obtaining informed consent, the independent medical staff member took the top envelope to assign each patient to the treatment regimen. We provided written instructions to all patients on how to take the medications. At the end of the treatment course, patients revisited the clinic to investigate side effects and evaluate compliance.

H. pylori Detection.

Eligible patients have undergone upper gastrointestinal endoscopy. Endoscopists have taken five gastric biopsies: two from the antrum, two from the body, and one from the incisura according to the Sydney system.¹⁸ Pathologists confirmed H. Pylori infection by microscopic examination after using haematoxylin, eosin, and Giemsa stains.¹⁹ We sent all biopsies to the central pathology laboratory of the same referral hospital.

At week eight, patients visited the central laboratory of our hospital and performed stool antigen tests by using the enzyme immunoassay method (EIA).²⁰

Safety and Compliance.

Adverse drug reactions and drug regimen compliance were assessed by a qualified physician. Adverse drug reactions were evaluated using open-ended questions in patient self-reports. We reported side effects such as nausea, vomiting, diarrhoea, melena, dysgeusia, and anorexia. We evaluated compliance by counting the number of pills unused of each medication and considered that the patient was compliant if he/she has taken at least 90% of the assigned treatment protocol. Medical laboratory workers were blinded to the treatment arm. Numerical data were shown as mean, while qualitative data were expressed as a ratio.

Authors reported the results according to CONSORT.)

Outcomes:

The primary outcome was the H pylori eradication rates of the initially assigned treatment according to intention to treat analysis (ITT), and per-protocol analysis (PPA).

Sample size and statistical analysis:

Our sample size (N = 78) was planned before the study, based on Federico et al research. the eradication rate based on ITT was 0.92 % in modified concomitant levofloxacin-containing therapy.²¹ We used tinidazole instead of metronidazole in the doxycycline-bismuth regimen for the first time, so we assumed that the eradication rate was 0.5, which gave us the largest sample size.^{22,23} We used a power (1- β) of 99%, two tails test and Significance level(α) equal to 5%, with a 1:1 allocation ratio. Each treatment arm requires thirty-four patients.^{24,25} We added five patients to each group to compensate for the predicted dropout.^{26,27}

Statistical tests: Chi-square test (χ^2 -test) for categorical variables, and t-test for continuous data. We calculated the odds ratio with a 95% confidence interval. A P-value of less than 0.05 was considered statistically significant. We performed statistical analyses using SPSS (IBM Corp. Released in 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp).

Results:

We collected 226 patients diagnosed with H. pylori infection confirmed by biopsy. Seventy-eight treatment-naïve patients enrolled in this study (39 patients for each group), only one B-group patient didn't complete the follow-up. [Figure 1 and Table 1] summarizes the flow chart and baseline characteristics. The gender, mean age and pharmacological side effects were similar among treatment groups, except for melena, which occurred more frequently in the B-group.

H. Pylori infection was eradicated in thirty patients from the B-group, and thirty-two patients from the L-group. The eradication rates according to ITT and PPA analysis are summarised in a table (2). We didn't report serious adverse effects.

Table 1: Baseline characteristics of patients

Table 1
Baseline characteristics

	Bismuth subsalicylate and doxycycline	levofloxacin and tinidazole	P-value
Gender			
Male	21(55.3%)	20(51.3%)	0.821
Female	17(44.7%)	19(48.7%)	
Age (mean years $\pm$ SD)	41.82 $\pm$ 11.914	45.62 $\pm$ 17.994	0.223
Smoking	16(42.1%)	16(41%)	1.00
Alcoholic	2(5.3%)	0(2.5%)	0.240
Adverse events			
Anorexia	5(13.2%)	11(28.2%)	0.160
Nausea	10(26.3%)	5(12.8%)	0.160
Vomiting	7(18.4%)	4(10.3%)	0.347
Dysgeusia	7(18.4%)	11(28.2%)	0.421
Melena	11(28.9%)	0(0%)	$\leq$ 0.0001
Discoloured Tongue	1(2.6%)	0(0%)	0.494
Diarrhea	6(15.8%)	3(7.7%)	0.310

Table 2

Helicobacter pylori eradication rate in therapy in modified levofloxacin concomitant and modified bismuth quadruple therapy groups

	Modified levofloxacin concomitant	Modified bismuth quadruple	Odds Ratio (95% CI)	P-Value
ITT	82.1%	76.9%	1.371(0.454,4.146)	0.78
PPA	82.1%	78.9%	1.219(0.394,3.774)	0.78
CI = confidence interval, ITT = intention to treat analysis, PPA = per-protocol analysis				

Discussion:

Researchers globally observed a decline in the rate of H pylori eradication following standard triple therapies, thus requiring a search for new therapeutic approaches. [45–48] This randomized clinical trial included 78 patients from an area of high prevalence (≈15%) of clarithromycin and levofloxacin resistant H pylori strains.^{1,12,14,28,29} Both levofloxacin concomitant and bismuth-containing quadruple therapies are recommended as alternative first-line treatment according to the previously mentioned guidelines, particularly in regions with a high prevalence of clarithromycin resistance.^{13,15}

Our results showed that both regimens had a fair eradicating rate of H pylori. The eradication rate for modified levofloxacin concomitant protocol was 82.05% according to ITT analysis; while bismuth quadruple protocol had a PPA eradication rate of 78.94%, and 76.92% according to ITT analysis. The overall eradication rate of the levofloxacin regimen was about 3% higher than the bismuth quadruple regimen but the difference didn't reach statistical significance. The result of levofloxacin containing therapy can be regarded as Grade D standard, while the result of bismuth-containing therapy can be regarded as Grade F as proposed recently.³⁰ Our results are consistent with a meta-analysis by Essa et al. and similar research by Federico et al. in concomitant therapy, both studies showed that concomitant therapy is effective in the eradication of H.Pylori,^{21,31} while a meta-analysis by Niv et al. found that doxycycline had good efficacy in treatment H.Pylori infection.¹⁶ Even though this research treated patients for a longer period,³² our results didn't show the effectiveness mentioned in previous studies. We could explain these results by (1) H. Pylori resistance in CagA-homB + strains,³³ because health care providers overprescribe antibiotics—especially macrolides and fluoroquinolones—for treating respiratory, urinary and gynaecological infections,^{34–36} (2) outpatients incompliance to antibiotic regimen^{37,37–39} and (3) using locally produced drugs.^{40,41}

Our study has a few limitations: (1) The only method to investigate past medication was to interrogate patients, because of the absence of electronic medical records for patients, therefore, authors considered the patient “naïve” if he/she wasn't treated previously for H. Pylori infection; (2) we depended on patients to evaluate the compliance; and (3) we didn't perform a susceptibility test of H. Pylori to antibiotics, because it not available in Syria.

Our results showed that both regimens had an acceptable rate of eradication, and the difference didn't reach statistical significance. These results were highly promising in treating H. Pylori infection in Syria.

Conclusion:

The success rate of the standard triple therapy with clarithromycin or levofloxacin has declined substantially due to increasing antimicrobial resistance. ACG clinical guideline and Maastricht consensus recommended alternative regimens, including bismuth-containing quadruple therapy or non-bismuth concomitant therapy, as first-line therapies, particularly in areas with a high prevalence of clarithromycin resistance like Syria. Both studied regimens had equally reasonable efficacy with no serious adverse

events. Further studies will help select the best first-line empirical therapy in the Syrian population for Helicobacter-Pylori Infection.

List Of Abbreviations

PPA
per-protocol analysis
ITT
intention to treat analysis
q.i.d.
four times a day.
b.i.d.
twice a day.
q.d
Once a day.
ACG
American College of Gastroenterology
H. Pylori
Helicobacter Pylori
PPI
proton pump inhibitors

Declarations

Pre-Print

<https://www.researchsquare.com/article/rs-80097/>

Ethics approval and consent to participate:

Ethical Committee of the general assembly of Damascus hospital (Approval No:5-30-12-19).

A proper consent form was approved by the patients. It was clearly stated that only clinical information will be shared in research, without mentioning any personal details at any part of the article.

Consent for publication:

We transfer, assign, or otherwise convey all copyright ownership, including any rights incidental thereto, exclusively to the journal, if such work is published by the journal.

Availability of data and materials:

The dataset supporting the conclusions of this article is available in the [data.mendeley.com] repository, [https://data.mendeley.com/drafts/fzv77yzshx], and it will be available after 15 September 2021 to 15 September 2023

Competing interests:

The authors declare that there is no conflict of interest.

Funding:

None. No funding to declare.

Authors' contributions

all authors have read and approved the manuscript

	MA	MWA	KAE	KC
Concepts	✓	✓	✓	✓
Design	✓	✓	✓	✓
Definition of intellectual content	✓	✓	✓	✓
Literature search	✓	✓	✓	✓
Clinical studies	✓	✓	✓	✓
Experimental studies	✓	✓	✓	✓
Data acquisition	✓	✓	✓	✓
Data analysis	✓	✓	✓	✓
Statistical analysis	✓	×	×	×
Manuscript preparation	✓	✓	✓	✓

Acknowledgements: None

References

1. Hooi, J. K. Y. *et al.* Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology* **153**, 420–429 (2017).
2. Peterson, W. L. *Helicobacter pylori* and Peptic Ulcer Disease. *New England Journal of Medicine* **324**, 1043–1048 (1991).

3. Caselli, M. & Alvisi, V. Helicobacter pylori and peptic-ulcer disease. *The Lancet* **359**, 1943–1944 (2002).
4. Henriksson, A. E., Edman, A. C., Held, M. & Wadström, T. Helicobacter pylori and acute bleeding peptic ulcer. *Eur J Gastroenterol Hepatol* **7**, 769–771 (1995).
5. Ishaq, S. & Nunn, L. Helicobacter pylori and gastric cancer: a state of the art review. *Gastroenterol Hepatol Bed Bench* **8**, S6–S14 (2015).
6. Wotherspoon, A. C. Gastric MALT lymphoma and Helicobacter pylori. *Yale J Biol Med* **69**, 61–68 (1996).
7. Kim, B. J., Kim, H. S., Jang, H. J. & Kim, J. H. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. *Gastroenterol Res Pract* **2018**, (2018).
8. Monzón, H. *et al.* Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. *World J Gastroenterol* **19**, 4166–4171 (2013).
9. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* **61**, 1–241 (1994).
10. Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial | Gastroenterology | JAMA | JAMA Network.
<https://jamanetwork.com/journals/jama/fullarticle/197985>.
11. Ghotaslou, R., Leylabadlo, H. E. & Asl, Y. M. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. *World J Methodol* **5**, 164–174 (2015).
12. Savoldi, A., Carrara, E., Graham, D. Y., Conti, M. & Tacconelli, E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology* **155**, 1372-1382.e17 (2018).
13. Malfertheiner, P. *et al.* Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. *Gut* **66**, 6–30 (2017).
14. Cheha, K. M., Dib, S. O. A. & Alhalabi, M. M. Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience. *Avicenna J Med* **8**, 14–17 (2018).
15. Chey, W. D., Leontiadis, G. I., Howden, C. W. & Moss, S. F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *American Journal of Gastroenterology* **112**, (2017).
16. Niv, Y. Doxycycline in Eradication Therapy of Helicobacter pylori—a Systematic Review and Meta-Analysis. *Digestion* **93**, 167–173 (2016).
17. Moshkowitz, M. *et al.* One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. *Alimentary Pharmacology & Therapeutics* **10**, 1015–1019 (1996).

18. Satoh, K. *et al.* Biopsy sites suitable for the diagnosis of *Helicobacter pylori* infection and the assessment of the extent of atrophic gastritis. *Am. J. Gastroenterol.* **93**, 569–573 (1998).
19. Lee, J. Y. & Kim, N. Diagnosis of *Helicobacter pylori* by invasive test: histology. *Ann Transl Med* **3**, (2015).
20. Veijola, L., Myllyluoma, E., Korpela, R. & Rautelin, H. Stool antigen tests in the diagnosis of *Helicobacter pylori* infection before and after eradication therapy. *World J Gastroenterol* **11**, 7340–7344 (2005).
21. Federico, A. *et al.* Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of *Helicobacter pylori* infection. *Gastroenterology* **143**, 55-61.e1; quiz e13-14 (2012).
22. Martínez-Mesa, J., González-Chica, D. A., Bastos, J. L., Bonamigo, R. R. & Duquia, R. P. Sample size: how many participants do I need in my research? *Anais Brasileiros de Dermatologia* **89**, 609–615 (2014).
23. Omais, A. Sample size estimation and sampling techniques for selecting a representative sample. *Journal of Health Specialties* vol. 2 142–147 (2014).
24. Peacock, J. L. & Peacock, P. J. *Oxford Handbook of Medical Statistics. Oxford Handbook of Medical Statistics* (Oxford University Press).
25. Whitley, E. & Ball, J. Statistics review 4: Sample size calculations. *Crit Care* **6**, 335–341 (2002).
26. Gupta, K., Attri, J., Singh, A., Kaur, H. & Kaur, G. Basic concepts for sample size calculation: Critical step for any clinical trials! *Saudi J Anaesth* **10**, 328–331 (2016).
27. Sakpal, T. V. Sample size estimation in clinical trial. *Perspectives in Clinical Research* **1**, 67 (2010).
28. Eshraghian, A. Epidemiology of *Helicobacter pylori* infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. *World J. Gastroenterol.* **20**, 17618–17625 (2014).
29. Kuo, Y.-T. *et al.* Primary antibiotic resistance in *Helicobacter pylori* in the Asia-Pacific region: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* **2**, 707–715 (2017).
30. Graham, D. Y., Lu, H. & Yamaoka, Y. A Report Card to Grade *Helicobacter pylori* Therapy. *Helicobacter* **12**, 275–278 (2007).
31. Essa, A. S., Kramer, J. R., Graham, D. Y. & Treiber, G. *Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing 'concomitant therapy' versus triple therapy for Helicobacter pylori eradication. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]* (Centre for Reviews and Dissemination (UK), 2009).
32. Yuan, Y. *et al.* Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database Syst Rev* CD008337 (2013) doi:10.1002/14651858.CD008337.pub2.
33. Haddadi, M.-H., Negahdari, B., Asadolahi, R. & Bazargani, A. *Helicobacter pylori* antibiotic resistance and correlation with cagA motifs and homB gene. *Postgrad Med* 1–9 (2020) doi:10.1080/00325481.2020.1753406.

34. Levy, S. B., Star, L. & Kupferberg, E. D. The misuse of antibiotics. *Medical ethics (Burlington, Mass.)* **11**, 5–8 (2004).
35. Schroeck, J. L. *et al.* Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. *Antimicrobial agents and chemotherapy* **59**, 3848–3852 (2015).
36. Giono-Cerezo, S., Santos-Preciado, J. I., Morfin-Otero, M. D. R., Torres-Lopez, F. J. & Alcantar-Curiel, M. D. Antimicrobial resistance. Its importance and efforts to control it. *Gac Med Mex* **156**, 171–178 (2020).
37. Kardas, P. Patient compliance with antibiotic treatment for respiratory tract infections. *J. Antimicrob. Chemother.* **49**, 897–903 (2002).
38. Grob, P. R. Antibiotic prescribing practices and patient compliance in the community. *Scand J Infect Dis Suppl* **83**, 7–14 (1992).
39. Eells, S. J. *et al.* Relationship between Adherence to Oral Antibiotics and Postdischarge Clinical Outcomes among Patients Hospitalized with Staphylococcus aureus Skin Infections. *Antimicrobial Agents and Chemotherapy* **60**, 2941–2948 (2016).
40. Nsimba, S. E. D. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. *East Afr J Public Health* **5**, 205–210 (2008).
41. Caudron, J.-M. *et al.* Substandard medicines in resource-poor settings: a problem that can no longer be ignored. *Trop. Med. Int. Health* **13**, 1062–1072 (2008).

Figures

Figure 1

Flow of the study

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [HowdoweCalculateSampleSize.docx](#)
- [CONSORT.docx](#)